Eugia Pharma receives USFDA approval for Dasatinib Tablets
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The product will be launched in Q1FY26
The company does not expect this development to have any material impact on the current business operations
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Subscribe To Our Newsletter & Stay Updated